Search

Your search keyword '"Plana, Olivia D."' showing total 14 results
Start Over Author "Plana, Olivia D."
14 results on '"Plana, Olivia D."'

1. New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation

Author

Arwood, Matthew L., Liu, Yao, Harkins, Shannon K., Weinstock, David M., Yang, Lei, Stevenson, Kristen E., Plana, Olivia D., Dong, Jingyun, Cirka, Haley, Jones, Kristen L., Virtanen, Anniina T., Gupta, Dikshat G., Ceas, Amanda, Lawney, Brian, Yoda, Akinori, Leahy, Catharine, Hao, Mingfeng, He, Zhixiang, Choi, Hwan Geun, Wang, Yaning, Silvennoinen, Olli, Hubbard, Stevan R., Zhang, Tinghu, Gray, Nathanael S., and Li, Loretta S.

Published
2023
Full Text
View/download PDF

2. Supplementary Table 5 from Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

Author

Lossos, Chen, primary, Liu, Yunpeng, primary, Kolb, Kellie E., primary, Christie, Amanda L., primary, Van Scoyk, Alexandria, primary, Prakadan, Sanjay M., primary, Shigemori, Kay, primary, Stevenson, Kristen E., primary, Morrow, Sara, primary, Plana, Olivia D., primary, Fraser, Cameron, primary, Jones, Kristen L., primary, Liu, Huiyun, primary, Pallasch, Christian P., primary, Modiste, Rebecca, primary, Nguyen, Quang-De, primary, Craig, Jeffrey W., primary, Morgan, Elizabeth A., primary, Vega, Francisco, primary, Aster, Jon C., primary, Sarosiek, Kristopher A., primary, Shalek, Alex K., primary, Hemann, Michael T., primary, and Weinstock, David M., primary

Published
2023
Full Text
View/download PDF

3. Supplementary Table 4 from Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

Author

Lossos, Chen, primary, Liu, Yunpeng, primary, Kolb, Kellie E., primary, Christie, Amanda L., primary, Van Scoyk, Alexandria, primary, Prakadan, Sanjay M., primary, Shigemori, Kay, primary, Stevenson, Kristen E., primary, Morrow, Sara, primary, Plana, Olivia D., primary, Fraser, Cameron, primary, Jones, Kristen L., primary, Liu, Huiyun, primary, Pallasch, Christian P., primary, Modiste, Rebecca, primary, Nguyen, Quang-De, primary, Craig, Jeffrey W., primary, Morgan, Elizabeth A., primary, Vega, Francisco, primary, Aster, Jon C., primary, Sarosiek, Kristopher A., primary, Shalek, Alex K., primary, Hemann, Michael T., primary, and Weinstock, David M., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Table 2 from Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

Author

Lossos, Chen, primary, Liu, Yunpeng, primary, Kolb, Kellie E., primary, Christie, Amanda L., primary, Van Scoyk, Alexandria, primary, Prakadan, Sanjay M., primary, Shigemori, Kay, primary, Stevenson, Kristen E., primary, Morrow, Sara, primary, Plana, Olivia D., primary, Fraser, Cameron, primary, Jones, Kristen L., primary, Liu, Huiyun, primary, Pallasch, Christian P., primary, Modiste, Rebecca, primary, Nguyen, Quang-De, primary, Craig, Jeffrey W., primary, Morgan, Elizabeth A., primary, Vega, Francisco, primary, Aster, Jon C., primary, Sarosiek, Kristopher A., primary, Shalek, Alex K., primary, Hemann, Michael T., primary, and Weinstock, David M., primary

Published
2023
Full Text
View/download PDF

5. Data from Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

Author

Lossos, Chen, primary, Liu, Yunpeng, primary, Kolb, Kellie E., primary, Christie, Amanda L., primary, Van Scoyk, Alexandria, primary, Prakadan, Sanjay M., primary, Shigemori, Kay, primary, Stevenson, Kristen E., primary, Morrow, Sara, primary, Plana, Olivia D., primary, Fraser, Cameron, primary, Jones, Kristen L., primary, Liu, Huiyun, primary, Pallasch, Christian P., primary, Modiste, Rebecca, primary, Nguyen, Quang-De, primary, Craig, Jeffrey W., primary, Morgan, Elizabeth A., primary, Vega, Francisco, primary, Aster, Jon C., primary, Sarosiek, Kristopher A., primary, Shalek, Alex K., primary, Hemann, Michael T., primary, and Weinstock, David M., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Table 6 from Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

Author

Lossos, Chen, primary, Liu, Yunpeng, primary, Kolb, Kellie E., primary, Christie, Amanda L., primary, Van Scoyk, Alexandria, primary, Prakadan, Sanjay M., primary, Shigemori, Kay, primary, Stevenson, Kristen E., primary, Morrow, Sara, primary, Plana, Olivia D., primary, Fraser, Cameron, primary, Jones, Kristen L., primary, Liu, Huiyun, primary, Pallasch, Christian P., primary, Modiste, Rebecca, primary, Nguyen, Quang-De, primary, Craig, Jeffrey W., primary, Morgan, Elizabeth A., primary, Vega, Francisco, primary, Aster, Jon C., primary, Sarosiek, Kristopher A., primary, Shalek, Alex K., primary, Hemann, Michael T., primary, and Weinstock, David M., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Table 3 from Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

Author

Lossos, Chen, primary, Liu, Yunpeng, primary, Kolb, Kellie E., primary, Christie, Amanda L., primary, Van Scoyk, Alexandria, primary, Prakadan, Sanjay M., primary, Shigemori, Kay, primary, Stevenson, Kristen E., primary, Morrow, Sara, primary, Plana, Olivia D., primary, Fraser, Cameron, primary, Jones, Kristen L., primary, Liu, Huiyun, primary, Pallasch, Christian P., primary, Modiste, Rebecca, primary, Nguyen, Quang-De, primary, Craig, Jeffrey W., primary, Morgan, Elizabeth A., primary, Vega, Francisco, primary, Aster, Jon C., primary, Sarosiek, Kristopher A., primary, Shalek, Alex K., primary, Hemann, Michael T., primary, and Weinstock, David M., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table 7 from Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

Author

Lossos, Chen, primary, Liu, Yunpeng, primary, Kolb, Kellie E., primary, Christie, Amanda L., primary, Van Scoyk, Alexandria, primary, Prakadan, Sanjay M., primary, Shigemori, Kay, primary, Stevenson, Kristen E., primary, Morrow, Sara, primary, Plana, Olivia D., primary, Fraser, Cameron, primary, Jones, Kristen L., primary, Liu, Huiyun, primary, Pallasch, Christian P., primary, Modiste, Rebecca, primary, Nguyen, Quang-De, primary, Craig, Jeffrey W., primary, Morgan, Elizabeth A., primary, Vega, Francisco, primary, Aster, Jon C., primary, Sarosiek, Kristopher A., primary, Shalek, Alex K., primary, Hemann, Michael T., primary, and Weinstock, David M., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 1 from Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

Author

Lossos, Chen, primary, Liu, Yunpeng, primary, Kolb, Kellie E., primary, Christie, Amanda L., primary, Van Scoyk, Alexandria, primary, Prakadan, Sanjay M., primary, Shigemori, Kay, primary, Stevenson, Kristen E., primary, Morrow, Sara, primary, Plana, Olivia D., primary, Fraser, Cameron, primary, Jones, Kristen L., primary, Liu, Huiyun, primary, Pallasch, Christian P., primary, Modiste, Rebecca, primary, Nguyen, Quang-De, primary, Craig, Jeffrey W., primary, Morgan, Elizabeth A., primary, Vega, Francisco, primary, Aster, Jon C., primary, Sarosiek, Kristopher A., primary, Shalek, Alex K., primary, Hemann, Michael T., primary, and Weinstock, David M., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figures and Methods from Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

Author

Lossos, Chen, primary, Liu, Yunpeng, primary, Kolb, Kellie E., primary, Christie, Amanda L., primary, Van Scoyk, Alexandria, primary, Prakadan, Sanjay M., primary, Shigemori, Kay, primary, Stevenson, Kristen E., primary, Morrow, Sara, primary, Plana, Olivia D., primary, Fraser, Cameron, primary, Jones, Kristen L., primary, Liu, Huiyun, primary, Pallasch, Christian P., primary, Modiste, Rebecca, primary, Nguyen, Quang-De, primary, Craig, Jeffrey W., primary, Morgan, Elizabeth A., primary, Vega, Francisco, primary, Aster, Jon C., primary, Sarosiek, Kristopher A., primary, Shalek, Alex K., primary, Hemann, Michael T., primary, and Weinstock, David M., primary

Published
2023
Full Text
View/download PDF

11. Mechanisms of lymphoma clearance induced by high-dose alkylating agents

Author

Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology. Institute for Medical Engineering & Science, Massachusetts Institute of Technology. Department of Chemistry, Ragon Institute of MGH, MIT and Harvard, Lossos, Chen, Liu, Yunpeng, Kolb, Kellie E, Christie, Amanda L, van Scoyk, Alexandria, Prakadan, Sanjay M, Shigemori, Kay, Stevenson, Kristen E, Morrow, Sara, Plana, Olivia D, Fraser, Cameron, Jones, Kristen L, Liu, Huiyun, Pallasch, Christian P, Modiste, Rebecca, Nguyen, Quang-De, Craig, Jeffrey W, Morgan, Elizabeth A, Vega, Francisco, Aster, Jon C, Sarosiek, Kristopher A, Shalek, Alex K, Hemann, Michael T, Weinstock, David M, Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology. Institute for Medical Engineering & Science, Massachusetts Institute of Technology. Department of Chemistry, Ragon Institute of MGH, MIT and Harvard, Lossos, Chen, Liu, Yunpeng, Kolb, Kellie E, Christie, Amanda L, van Scoyk, Alexandria, Prakadan, Sanjay M, Shigemori, Kay, Stevenson, Kristen E, Morrow, Sara, Plana, Olivia D, Fraser, Cameron, Jones, Kristen L, Liu, Huiyun, Pallasch, Christian P, Modiste, Rebecca, Nguyen, Quang-De, Craig, Jeffrey W, Morgan, Elizabeth A, Vega, Francisco, Aster, Jon C, Sarosiek, Kristopher A, Shalek, Alex K, Hemann, Michael T, and Weinstock, David M

Abstract

© 2019 American Association for Cancer Research. The extraordinary activity of high-dose cyclophosphamide against some high-grade lymphomas was described nearly 60 years ago. Here we address mechanisms that mediate cyclophosphamide activity in bona fide human double-hit lymphoma. We show that antibody resistance within the bone marrow (BM) is not present upon early engraftment but develops during lymphoma progression. This resistance required a high tumor:macrophage ratio, was recapitulated in spleen by partial macrophage depletion, and was overcome by multiple, high-dose alkylating agents. Cyclophosphamide induced endoplasmic reticulum (ER) stress in BM-resident lymphoma cells in vivo that resulted in ATF4-mediated paracrine secretion of VEGFA, massive macrophage infiltration, and clearance of alemtuzumab-opsonized cells. BM macrophages isolated after cyclophosphamide treatment had increased phagocytic capacity that was reversed by VEGFA blockade or SYK inhibition. Single-cell RNA sequencing of these macrophages identified a “super-phagocytic” subset that expressed CD36/FCGR4. Together, these findings define a novel mechanism through which high-dose alkylating agents promote macrophage-dependent lymphoma clearance. SIGNIFICANCE: mAbs are effective against only a small subset of cancers. Herein, we recapitulate compartment-specific antibody resistance and define an ER stress–dependent mechanism induced by high-dose alkylating agents that promotes phagocytosis of opsonized tumor cells. This approach induces synergistic effects with mAbs and merits testing across additional tumor types.

Published
2021

12. Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

Author

Lossos, Chen, primary, Liu, Yunpeng, additional, Kolb, Kellie E., additional, Christie, Amanda L., additional, Van Scoyk, Alexandria, additional, Prakadan, Sanjay M., additional, Shigemori, Kay, additional, Stevenson, Kristen E., additional, Morrow, Sara, additional, Plana, Olivia D., additional, Fraser, Cameron, additional, Jones, Kristen L., additional, Liu, Huiyun, additional, Pallasch, Christian P., additional, Modiste, Rebecca, additional, Nguyen, Quang-De, additional, Craig, Jeffrey W., additional, Morgan, Elizabeth A., additional, Vega, Francisco, additional, Aster, Jon C., additional, Sarosiek, Kristopher A., additional, Shalek, Alex K., additional, Hemann, Michael T., additional, and Weinstock, David M., additional

Published
2019
Full Text
View/download PDF

13. Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

Author

Lossos, Chen, Liu, Yunpeng, Kolb, Kellie E., Christie, Amanda L., Van Scoyk, Alexandria, Prakadan, Sanjay M., Shigemori, Kay, Stevenson, Kristen E., Morrow, Sara, Plana, Olivia D., Fraser, Cameron, Jones, Kristen L., Liu, Huiyun, Pallasch, Christian P., Modiste, Rebecca, Craig, Jeffrey W., Morgan, Elizabeth A., Vega, Francisco, Aster, Jon C., Sarosiek, Kristopher A., Shalek, Alex K., Hemann, Michael T., Weinstock, David M., Lossos, Chen, Liu, Yunpeng, Kolb, Kellie E., Christie, Amanda L., Van Scoyk, Alexandria, Prakadan, Sanjay M., Shigemori, Kay, Stevenson, Kristen E., Morrow, Sara, Plana, Olivia D., Fraser, Cameron, Jones, Kristen L., Liu, Huiyun, Pallasch, Christian P., Modiste, Rebecca, Craig, Jeffrey W., Morgan, Elizabeth A., Vega, Francisco, Aster, Jon C., Sarosiek, Kristopher A., Shalek, Alex K., Hemann, Michael T., and Weinstock, David M.

Abstract

The extraordinary activity of high-dose cyclophosphamide against some high-grade lymphomas was described nearly 60 years ago. Here we address mechanisms that mediate cyclophosphamide activity in bona fide human double-hit lymphoma. We show that antibody resistance within the bone marrow (BM) is not present upon early engraftment but develops during lymphoma progression. This resistance required a high tumor:macrophage ratio, was recapitulated in spleen by partial macrophage depletion, and was overcome by multiple, high-dose alkylating agents. Cyclophosphamide induced endoplasmic reticulum (ER) stress in BM-resident lymphoma cells in vivo that resulted in ATF4-mediated paracrine secretion of VEGFA, massive macrophage infiltration, and clearance of alemtuzumab-opsonized cells. BM macrophages isolated after cyclophosphamide treatment had increased phagocytic capacity that was reversed by VEGFA blockade or SYK inhibition. Single-cell RNA sequencing of these macrophages identified a super-phagocytic subset that expressed CD36/FCGR4. Together, these findings define a novel mechanism through which high-dose alkylating agents promote macrophage-dependent lymphoma clearance. SIGNIFICANCE: mAbs are effective against only a small subset of cancers. Herein, we recapitulate compartment-specific antibody resistance and define an ER stress-dependent mechanism induced by high-dose alkylating agents that promotes phagocytosis of opsonized tumor cells. This approach induces synergistic effects with mAbs and merits testing across additional tumor types.

Published
2019

14. Alkylating Agent-Induced ER Stress Overcomes Microenvironmental Resistance to Lymphoma Therapy

Author

Lossos, Chen, primary, Kolb, Kellie E., additional, Christie, Amanda L., additional, Scoyk, Alexandria Van, additional, Prakadan, Sanjay, additional, Shigamori, Kay, additional, Stevenson, Kristen, additional, Morrow, Sara, additional, Plana, Olivia D., additional, Fraser, Cameron, additional, Liu, Huiyun, additional, Pallasch, Christian C., additional, Modiste, Rebecca, additional, Nguyen, Quang-De, additional, Craig, Jeffrey W., additional, Morgan, Elizabeth A., additional, Aster, Jon C., additional, Sarosiek, Kristopher A., additional, Shalek, Alex K., additional, Hemann, Michael T., additional, and Weinstock, David M., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results